Table 2.
Microorganisms and antibiotic susceptibility profiles of NSEE and NSOCE isolates, December 2011 to December 2016
| NSEE (N=49) | NSOCE (N=150) | |
|---|---|---|
| Bacterial species | ||
| Klebsiella pneumoniae | 14 (28.6%) | 106 (70.7%) |
| Escherichia coli | 16 (32.7%) | 21 (14.0%) |
| Enterobacter spp. | 19 (38.8%) | 19 (12.7%) |
| Other (Citrobacter spp., Proteus spp., Serratia marcescens) | 0 (0%) | 4 (2.7%) |
| Source | ||
| Urine | 19 (38.8%) | 69 (46.0%) |
| Intra-abdominal | 16 (32.7%) | 32 (21.3%) |
| Respiratory specimens | 6 (12.2%) | 17 (11.3%) |
| Wound swab | 6 (12.2%) | 18 (12.0%) |
| Blood | 2 (4.1%) | 14 (9.3%) |
| Amikacin (no. of isolates tested) | 49 | 148 |
| Susceptible, n | 40 (81.6%) | 96 (64.9%) |
| Intermediate, n | 2 (4.1%) | 1 (0.7%) |
| Resistant, n | 7 (14.3%) | 51 (34.5%) |
| Gentamicin (no. of isolates tested) | 49 | 148 |
| Susceptible, n | 22 (44.9%) | 56 (37.8%) |
| Intermediate, n | 1 (2.0%) | 5 (3.4%) |
| Resistant, n | 26 (53.1%) | 87 (58.8%) |
| Colistin (no. of isolates tested) | 49 | 148 |
| Susceptible, n | 46 (93.9%) | 137 (92.6%) |
| Intermediate, n | 0 (0%) | 0 (0%) |
| Resistant, n | 3 (6.1%) | 11 (7.4%) |
| Tigecycline (no. of isolates tested) | 49 | 148 |
| Susceptible, n | 44 (89.8%) | 135 (91.2%) |
| Intermediate, n | 3 (6.1%) | 7 (4.7%) |
| Resistant, n | 2 (4.1%) | 6 (4.1) |
| Imipenem (no. of isolates tested) | 49 | 150 |
| Susceptible, n | 49 (100%) | 35 (23.3%) |
| Intermediate, n | 0 (0%) | 20 (13.3%) |
| Resistant, n | 0 (0%) | 95 (63.3%) |
| Meropenem (no. of isolates tested) | 49 | 150 |
| Susceptible, n | 49 (100%) | 6 (4.0%) |
| Intermediate, n | 0 (0%) | 18 (12.0%) |
| Resistant, n | 0 (0%) | 126 (84.0%) |
| Doripenem (no. of isolates tested) | 49 | 148 |
| Susceptible, n | 49 (100%) | 23 (15.5%) |
| Intermediate, n | 0 (0%) | 27 (18.2%) |
| Resistant, n | 0 (0%) | 98 (66.2%) |
| Piperacillin/tazobactam (no. of isolates tested) | 49 | 147 |
| Susceptible, n | 8 (16.3%) | 6 (4.1%) |
| Intermediate, n | 4 (8.2%) | 10 (6.8%) |
| Resistant, n | 37 (75.5%) | 131 (89.1%) |
| Amoxicillin/clavulanate (no. of isolates tested) | 49 | 145 |
| Susceptible, n | 3 (6.1%) | 1 (0.7%) |
| Intermediate, n | 9 (18.4%) | 11 (7.6%) |
| Resistant, n | 37 (75.5%) | 133 (91.7%) |
| Ciprofloxacin (no. of isolates tested) | 49 | 148 |
| Susceptible, n | 9 (18.4%) | 15 (10.1%) |
| Intermediate, n | 2 (4.1%) | 6 (4.1%) |
| Resistant, n | 28 (57.1%) | 127 (85.8%) |
| Levofloxacin (no. of isolates tested) | 49 | 146 |
| Susceptible, n | 11 (22.4%) | 23 (15.8%) |
| Intermediate, n | 5 (10.2%) | 10 (6.8%) |
| Resistant, n | 33 (67.3%) | 113 (77.4%) |
Abbreviations: NSEE, carbapenem nonsusceptibility to ertapenem alone Enterobacteriaceae; NSOCE, non-susceptibility to other carbapenems (imipenem, meropenem, or doripenem) Enterobacteriaceae.